Search Results

You are looking at 31 - 40 of 383 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

bevacizumab/cisplatin/pemetrexed, which is only recommended for patients with unresectable disease and should only be considered for patients who are candidates to receive bevacizumab. 47 For patients with clinical stage IV MPM, sarcomatoid histology, or

Full access

Kristen Keon Ciombor and Tanios Bekaii-Saab

capecitabine, or single-agent irinotecan are still reasonable treatment options. 6 , 9 - 11 In addition, first-line capecitabine plus bevacizumab was recently shown to improve both progression-free survival and response rate compared with capecitabine alone in

Full access

Presented by: Robin Kate Kelley

+ bevacizumab led to a significant OS benefit compared with sorafenib in patients with locally advanced or metastatic and/or unresectable HCC who had no prior systemic therapy. The doublet also significantly improved the co–primary endpoint of progression

Full access

Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna

trial with FOLFOXIRI in BRAF mt mCRC resulted in a median OS of 24.1 months, which compared favorably with historical control patients. 7 A randomized phase III study recently evaluated 1L FOLFOXIRI + bevacizumab versus FOLFIRI + bevacizumab in

Full access

Philip E. Lammers and Leora Horn

, a necessary process in the growth and metastasis of solid tumors. 5 Bevacizumab is the only antiangiogenic therapy FDA-approved for NSCLC, 6 but other agents have been tested in advanced NSCLC. Currently, NCCN recommends that bevacizumab be

Full access

Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu, and Debra P. Ritzwoller

, azacytidine, bacille Calmette-Guérin, bendamustine, bevacizumab, busulfan, cetuximab, cyclophosphamide, cytarabine, daunorubicin, decitabine, docetaxel, doxorubicin, etoposide, fludarabine, fluorouracil, gemcitabine, idarubicin, interferon alfa-2a, interferon

Full access

Marjorie G. Zauderer and Lee M. Krug

been studied in mesothelioma and have shown low levels of activity. 39 - 42 Other inhibitors of angiogenesis continue to be explored in this disease. Bevacizumab Bevacizumab is a monoclonal antibody that binds to VEGF. In multiple tumor types

Full access

Eric H. Bent, Eric Wehrenberg-Klee, Eugene J. Koay, Lipika Goyal, and Jennifer Y. Wo

, wherein 9 systemic therapy regimens have full or accelerated FDA approval. Atezolizumab combined with bevacizumab is now a standard first-line treatment for unresectable or metastatic HCC based on the landmark IMbrave150 study showing the superiority of

Full access

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

cytoreduction is an option for those with extensive stage IIIC or stage IV disease. 23 Primary Adjuvant Treatment Using Bevacizumab in Combination With Chemotherapy The panel members had a major disagreement about recommending the addition of bevacizumab

Full access

John H. Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F. Siadak, Maria Corinna Palanca-Wessels, Junhua Yu, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, and Tanios S. Bekaii-Saab

days or a switch to/addition of a regimen after a 15- or 60-day gap in therapy (depending on the treatment/regimen; the addition of bevacizumab to chemotherapy was not counted as a new LoT unless there was a gap in therapy of >180 days). 19 , 20